Market revenue in 2023 | USD 56.1 million |
Market revenue in 2030 | USD 69.1 million |
Growth rate | 3% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | Thermo Fisher Scientific Inc, Qiagen NV, Illumina Inc, Roche Holding AG ADR, BD, Agilent Technologies Inc, Myriad Genetics Inc, Koninklijke Philips NV, Abbott Laboratories, Hitachi Ltd, Danaher Corp, Prestige Medical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer diagnostic market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 63.81% in 2023. Horizon Databook has segmented the Spain pancreatic cancer diagnostic market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
In November 2022, the Spanish Society of Medical Oncology (SEOM) and other associations used World Pancreatic Cancer Day to highlight the impact of pancreatic cancer in Spain, with around 9,252 cases diagnosed in 2021. Radiology, particularly through CT procedures, plays a pivotal role in diagnosing and staging pancreatic cancer, crucial for treatment planning.
SEOM acknowledged the Spanish Society of Diagnostic Imaging of the Abdomen (SEDIA) for supporting specialists in this area. This advocacy underscores the importance of radiology in guiding clinical decisions and managing pancreatic cancer effectively in Spain.
In January 2022, researchers from Hospital del Mar and IIBB-CSIC-IDIBAPS identified a new early diagnostic marker for pancreatic cancer, published in eBio Medicine. The marker, soluble AXL protein, detected via a simple blood test, distinguishes pancreatic ductal adenocarcinoma from chronic pancreatitis.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain pancreatic cancer diagnostic market , including forecasts for subscribers. This country databook contains high-level insights into Spain pancreatic cancer diagnostic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account